OSR Holdings

What OSR Holdings does

OSR Holdings (recently rebranded as OSR Health, Inc., effective June 11, 2026) is a publicly traded healthcare holding company operating under a hub-and-spoke model, listed on the NASDAQ Capital Market under ticker OSRH since February 2025. The parent entity centralizes IP ownership and capital allocation across four wholly-owned subsidiaries: Vaximm AG (Switzerland) developing VXM01, a clinical-stage oral T-cell immunotherapy targeting VEGFR-2 with FDA and EMA Orphan Drug Designation in glioblastoma and pancreatic cancer; Darnatein (South Korea) advancing AI-enhanced chimeric Activin/BMP7 biologics DRT-101 for osteoarthritis cartilage regeneration and DRT-102 for spinal bone repair; Woori IO (South Korea) commercializing Glucheck, a noninvasive near-infrared spectroscopy glucose monitoring system validated in a 145-participant pilot study meeting ISO 15197:2013 standards; and RMC (South Korea), a profitable medical device distributor expanding into 4th-party logistics (4PL) services for hospitals and device manufacturers.

Name

OSR Holdings

Legal name

OSR Health, Inc.

Website

https://osr-holdings.com

Company type

Public

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

OSR Health (formerly OSR Holdings) is a NASDAQ-listed healthcare holding company operating a hub-and-spoke model with four wholly-owned subsidiaries developing oral cancer immunotherapies (Vaximm), regenerative biologics (Darnatein), noninvasive glucose monitoring devices (Woori IO), and medical device distribution (RMC) across the US, South Korea, and Switzerland.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)

akta.pro secondary industry

Material Characterization & Spectroscopy (NMR/FTIR/MS) (HLAGADAK)

Keywords

• Biopharmaceutical development
• Oral immunotherapy
• Regenerative biologics
• Medical device distribution
• Noninvasive glucose monitoring

Headquarters

HQ city

Paju

HQ country

South Korea

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Licensing and Milestone Payments: OSR Holdings generates revenue through licensing deals where partners pay upfront fees, development and regulatory milestones, and commercial milestones. The VXM01 deal with BCM Europe includes $30M upfront, up to $815M in milestones, and downstream royalties after partner cost recovery.
2. Medical Device Distribution: RMC subsidiary distributes neurovascular intervention medical devices and systems in South Korea, with expansion into 4th-party logistics (4PL) services providing import licensing, regulatory, and logistics consolidation for hospitals and device manufacturers.
3. Technology Commercialization: Revenue from noninvasive glucose monitoring technology through consumer wellness wearables (accelerated path per FDA guidance) and medical-grade CGM devices. Woori IO targeting both consumer and clinical markets.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels3 records

Core offering

OSR Holdings is a healthcare holding company that develops and commercializes therapeutics, biologics, and medical devices through its subsidiaries. Its core assets include VXM01, an oral T-cell immunotherapy for solid tumors (licensed to BCM Europe AG for up to $815M); DRT-101 and DRT-102, design-augmented biologics for osteoarthritis and spinal bone repair; Glucheck, a noninvasive glucose monitoring device using NIRS technology; and medical device distribution services through RM Communications. The company operates a hub-and-spoke model centralizing IP ownership and capital allocation at the parent while subsidiaries execute development and commercialization.

Product overview

OSR Health operates as a hub-and-spoke healthcare group with a diversified portfolio of subsidiary companies. The parent holding company, publicly listed on NASDAQ (ticker OSRH) and recently rebranded from OSR Holdings in June 2026, coordinates its four wholly-owned subsidiaries: Vaximm AG, developing the VXM01 oral T-cell immunotherapy for cancer; Darnatein, advancing AI-designed biologics DRT-101 (for osteoarthritis) and DRT-102 (for spinal bone repair); Woori IO, providing the Glucheck noninvasive glucose monitoring system using near-infrared spectroscopy; and RMC (RM Communications), a medical device distribution and 4th-party logistics platform. The company also operates a tokenization strategy through a planned OSRT security token, and holds the full VXM01 intellectual property portfolio acquired in May 2026 for $30 million, under a licensing deal with BCM Europe AG worth up to $815 million in milestones. The subsidiaries operate with agility and focus on developing transformative medicines and medical technologies, while the parent centralizes expertise, resources, and IP ownership.

Differentiator

Problem solved

Functional benefit

Brands

• Vaximm: Oral T-cell immunotherapy platform for cancer; lead candidate VXM01 targeting VEGFR-2
• Darnatein
• Glucheck
• OSRT

Quantifiable outcome

• Over 90% accuracy in glucose measurements with <8% below 74% error threshold in pilot study
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

Six partnerships are on record, tiered major, minor, core and supporting.

• Sinopharm Group Beijing HuahongmajorStrategic or Co-development Partner · 19 March 2026Woori IO signed mutual NDA with Sinopharm Group Beijing Huahong, China's largest pharmaceutical and medical device distributor ($81B revenue in 2024), to evaluate regulatory, clinical, and commercial pathways for glucose monitoring technology in China's diabetes market of 140+ million patients.
• SillaJenminorStrategic or Co-development Partner · 16 March 2026Vaximm AG in ongoing but non-binding discussions with SillaJen regarding potential licensing arrangement for Pexa-Vec oncolytic immunotherapy for renal cell carcinoma, and preliminary discussions about acquiring ~16% of SillaJen's outstanding shares.
• Samsung ElectronicscoreStrategic or Co-development Partner · 14 October 2025Woori IO collaborating with Samsung Electronics on proof-of-concept study for noninvasive glucose monitoring via Samsung's C-Lab Outside program. Partnership includes non-dilutive funding and participation of Samsung employees in initial trials. Seeks to integrate glucose monitoring technology into Samsung wearable devices.
• Taekwondo CooperativeminorOthers · 22 May 2025MOU signed for blockchain-based OSRH Token initiative with TAC utility token integration. Taekwondo Cooperative leads global Taekwondo community blockchain adoption with 70M practitioners in 190 countries.
• BioToxTechsupportingImplementation/ SI/ Consulting Partner · 9 April 2025IND-enabling preclinical studies collaboration for DRT-101 osteoarthritis treatment with BioToxTech, a publicly-listed CRO based in South Korea, and University of California San Diego.
• Korea University Guro HospitalsupportingStrategic or Co-development Partner · 9 May 2023Woori IO conducted pilot study for Glucheck glucose monitoring system at Korea University Guro Hospital, validating accuracy and precision across 145 participants against reference devices. Study completed May-September 2023.

Scale indicators9 records

Recent moves6 records

Direct peers

• Roivant Sciences: Clinical-stage biotech holding company operating a hub-and-spoke model with multiple subsidiary 'Vants' developing differentiated therapies across various therapeutic areas. Directly comparable to OSR's holding structure centralizing IP and capital allocation across diverse biotech/medtech subsidiaries.
• PureTech Health: Clinical-stage biotherapeutics company with a hub-and-spoke model developing multiple therapeutic candidates through wholly-owned and controlled subsidiaries. Similar holding-company approach to OSR's Vaximm, Darnatein, Woori IO, and RMC structure with diversified clinical assets.
• Know Labs: Developer of noninvasive glucose monitoring technology using radio frequency (RF) spectroscopy, targeting the same needle-free CGM market as Woori IO's NIRS-based Glucheck. Most direct technological peer in the truly noninvasive glucose monitoring category.
• Mesoblast: Regenerative medicine company developing cellular therapies and biologics for inflammatory diseases, including musculoskeletal conditions. Directly comparable to Darnatein's DRT-101 (osteoarthritis) and DRT-102 (spinal bone repair) pipeline in the regenerative biologics space.
• Anika Therapeutics: Joint preservation and regenerative medicine company developing hyaluronic acid-based therapies for osteoarthritis. Directly comparable to Darnatein's DRT-101 disease-modifying osteoarthritis drug candidate in the joint regeneration space.
• BridgeBio Pharma: Clinical-stage biotech with multiple programs targeting genetic diseases and cancers across subsidiary structures. Comparable holding-company approach to OSR with parallel development of multiple clinical assets and similar reliance on licensing and partnership economics.
• Ligand Pharmaceuticals: Biopharmaceutical company operating a royalty/holding model with diversified portfolio of funded programs and partnerships. Comparable business model to OSR's hub-and-spoke approach, with revenue derived from licensing and milestone-based deals across a portfolio of therapeutic assets.

Broad incumbents

• BioNTech: Larger established immunotherapy and cancer vaccine company with mRNA-based platforms. Comparable therapeutic area focus to Vaximm's VXM01 oral T-cell immunotherapy, though BioNTech operates at significantly greater scale and uses a different technology modality.
• Dexcom: Market leader in continuous glucose monitoring (CGM) systems with established FDA-approved products. The dominant incumbent in the glucose monitoring market that Woori IO's Glucheck aims to disrupt with truly needle-free technology.
• Abbott Diabetes Care: Established medical device company with the Freestyle Libre CGM system dominating the consumer glucose monitoring market. Major incumbent competitor to Woori IO's NIRS technology in the global diabetes care space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/OSRHoldings
• YouTubeyoutube.com/@osr-holdings
• LinkedInlinkedin.com/company/osr-holdings

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries4 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OSR Holdings